Show brief item record

dc.contributor.authorDe la Guardia, Carolina
dc.contributor.authorStephens, David E.
dc.contributor.authorDang, Hang T.
dc.contributor.authorQuijada, Mario
dc.contributor.authorLarionov, Oleg V.
dc.contributor.authorLleonart, Ricardo
dc.date.accessioned2021-04-19T15:05:39Z
dc.date.available2021-04-19T15:05:39Z
dc.date.issued3/16/2018
dc.identifierdoi: 10.3390/molecules23030672
dc.identifier.citationMolecules 23 (3): 672 (2018)
dc.identifier.urihttps://hdl.handle.net/20.500.12588/404
dc.description.abstractDengue virus causes dengue fever, a debilitating disease with an increasing incidence in many tropical and subtropical territories. So far, there are no effective antivirals licensed to treat this virus. Here we describe the synthesis and antiviral activity evaluation of two compounds based on the quinoline scaffold, which has shown potential for the development of molecules with various biological activities. Two of the tested compounds showed dose-dependent inhibition of dengue virus serotype 2 in the low and sub micromolar range. The compounds <b>1</b> and <b>2</b> were also able to impair the accumulation of the viral envelope glycoprotein in infected cells, while showing no sign of direct virucidal activity and acting possibly through a mechanism involving the early stages of the infection. The results are congruent with previously reported data showing the potential of quinoline derivatives as a promising scaffold for the development of new antivirals against this important virus.
dc.titleAntiviral Activity of Novel Quinoline Derivatives against Dengue Virus Serotype 2
dc.date.updated2021-04-19T15:05:39Z


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show brief item record